Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Watts JM, et al. Among authors: forsyth s. Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10. Lancet Haematol. 2023. PMID: 36370742 Clinical Trial.
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.
Forsyth S, Schroeder P, Geib J, Vrishabhendra L, Konstantinidis DG, LaSalvia K, Ribadeneira MD, Wu E, Kelly P, Kalfa TA. Forsyth S, et al. Clin Pharmacol Drug Dev. 2022 May;11(5):654-665. doi: 10.1002/cpdd.1058. Epub 2022 Jan 12. Clin Pharmacol Drug Dev. 2022. PMID: 35019238 Free PMC article. Clinical Trial.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V. de la Fuente MI, et al. Among authors: forsyth s. Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139. Neuro Oncol. 2023. PMID: 35639513 Free PMC article. Clinical Trial.
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.
Saraf SL, Hagar RW, Idowu M, Osunkwo I, Cruz K, Kuypers FA, Brown RC, Geib J, Ribadeneira MD, Schroeder P, Wu E, Forsyth S, Kelly PF, Kalfa TA, Telen MJ. Saraf SL, et al. Among authors: forsyth s. Blood Adv. 2024 Apr 19:bloodadvances.2023012467. doi: 10.1182/bloodadvances.2023012467. Online ahead of print. Blood Adv. 2024. PMID: 38640200
Proximal humerus reconstruction in reverse total shoulder arthroplasty with proximal humeral bone loss using a lower trapezius tendon transfer with Achilles tendon-bone allograft: surgical technique and report of 2 cases.
Eckers F, Hochreiter B, Forsyth S, Ek ET. Eckers F, et al. Among authors: forsyth s. JSES Int. 2024 Jan 18;8(3):508-514. doi: 10.1016/j.jseint.2023.12.010. eCollection 2024 May. JSES Int. 2024. PMID: 38707582 Free PMC article. No abstract available.
Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19.
Camirand-Lemyre F, Merson L, Tirupakuzhi Vijayaraghavan BK, Burrell AJC, Citarella BW, Domingue MP, Lévesque S, Usuf E, Wils EJ, Ohshimo S, Martin-Loeches I, Sandulescu O, Laake JH, Lamontagne F; ISARIC Clinical Characterisation Group. Camirand-Lemyre F, et al. JAMA Netw Open. 2023 Dec 1;6(12):e2346502. doi: 10.1001/jamanetworkopen.2023.46502. JAMA Netw Open. 2023. PMID: 38147336 Free PMC article.
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
Ng K, Metcalf R, Sacco J, Kong A, Wheeler G, Forsyth S, Bhat R, Ward J, Ensell L, Lowe H, Spanswick V, Hartley J, White L, Lloyd-Dehler E, Forster M. Ng K, et al. Among authors: forsyth s. BMJ Open. 2023 Nov 27;13(11):e070391. doi: 10.1136/bmjopen-2022-070391. BMJ Open. 2023. PMID: 38011968 Free PMC article.
264 results